This episode of Industry Insights features Nataliia Beztsinna, PhD, and Marten Hornsveld, PhD, from Crown Bioscience as they describe how reconstituted TME and patient-derived ex vivo tissue assays can best be used within the drug development pipeline.
In this episode of Industry Insights, Saskia De Man, PhD, Marrit Putker, PhD, and Pirouz Daftarian, PhD, from Crown Bioscience discuss assays and methods for evaluating T cell therapeutics, including organoids, co-cultures, and high content imaging.
Marrit Putker, Saskia De Man, and Pirouz Daftarian from Crown Bioscience discuss T cell-directed immunotherapy on the cancer-immunity cycle, including mechanisms and targets capable of modulating and enhancing T cell activity and the application of methods and models including organoids and high content imaging.
In this episode of Industry Insights, Rajendra Kumari, PhD, and Gera Goverse, PhD, from Crown Bioscience answer questions about in vivo, in vitro, and ex vivo technologies and methods that can be used for immuno-oncology research along each step of the cancer-immunity cycle.
This episode of Share Science features Amy Sheng from Sino Biological, who shares how nanobodies are expected to revolutionize antibody-based drug therapies for a wide range of pathological conditions and especially cancer immunotherapy!
Cancer immunotherapy has undoubtedly expanded the cancer treatment landscape and improved patient outlook, which can in part be attributed to the recognition of the importance of the cancer-immunity cycle as a whole. In this blog, we provide an overview of the cancer-immunity cycle and highlight some preclinical models that can facilitate cancer immunotherapy research.